Skip to content

Organogenesis Holdings Inc.

ORGO· NasdaqCore metricsCIK 1661181

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -8.46%
Market cap
$125.35M
129.8M shares
Filings
673
$45.46M
Q3 2026+17.0% FY25 yoy
-$29.63M
Q3 2026+4,201.0% FY25 yoy
-$29.49M
Q3 2026N/M FY25 yoy
-$34.83M
Q3 2026derivedN/M FY25 yoy
-$0.25
Q3 2026N/M FY25 yoy
$21.33M
Q3 2026−30.9% FY25 yoy
$125.35M
—
0.4×
1.0×
-0.05%
—

Twelve months to Sep 30, 2026 · derived

Price

$0.965785.14%$5.5343past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$564.17MFY 2025
$564.17M0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$564,169,000reported
FY 20242024-12-31$482,043,000reported
FY 20232023-12-31$433,140,000reported
FY 20222022-12-31$450,893,000reported
FY 20212021-12-31$467,359,000 revisedreported
FY 20202020-12-31$338,298,000reported
FY 20192019-12-31$260,981,000reported
FY 20182018-12-31$193,449,000reported
FY 20172017-12-31$198,508,000 revisedreported
FY 20162016-12-31$138,732,000 revisedreported

Capital returns

Dividends and buybacks · FY2022 to FY2024
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2024—$25.48M$25.48M—126.85M sh−3.9%610.1%
FY2023—$0.00$0.00—131.96M sh+0.6%0.0%
FY2022—$0.00$0.00—131.18M sh+1.6%—

Segments

Products
Revenue by Products, FY2018 to FY2025FY2018Advanced Wound Care · FY2018 · $164.33MSurgical & Sports Medicine · FY2018 · $29.12MFY2019Advanced Wound Care · FY2019 · $220.74MSurgical & Sports Medicine · FY2019 · $40.24MFY2020Advanced Wound Care · FY2020 · $294.62MSurgical & Sports Medicine · FY2020 · $43.67MFY2021Advanced Wound Care · FY2021 · $430.24MSurgical & Sports Medicine · FY2021 · $37.12MFY2022Advanced Wound Care · FY2022 · $422.23MSurgical & Sports Medicine · FY2022 · $28.66MFY2023Net product revenue · FY2023 · $433.14MAdvanced Wound Care · FY2023 · $405.51MSurgical & Sports Medicine · FY2023 · $27.63MFY2024Net product revenue · FY2024 · $482.04MAdvanced Wound Care · FY2024 · $453.64MSurgical & Sports Medicine · FY2024 · $28.40MFY2025Net product revenue · FY2025 · $563.03MGrant income · FY2025 · $1.14M
LineFY2025ShareChange
Net product revenue$563.03M100%+16.8%
Grant income$1.14M0.2%—
Advanced Wound Care———
Surgical & Sports Medicine———
Total$564.17M

From the 10-K filed Feb 26, 2026ORGO

Pharmaceutical preparations

Organogenesis Holdings Inc. is the 52nd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Organogenesis Holdings Inc. · CIK 1661181 · Engraved from SEC EDGAR